AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9989329 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief smoking cessation intervention
Number of subjects: 0
Study 9989329 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (non-participants)
Number of subjects: 0
Study 8062489 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (2 gm) with adinazolam (60 mg)
Number of subjects: 16
Study 8062489 — intervention group
Group type: COMPARATOR
Intervention: Adinazolam (60 mg)
Number of subjects: 16
Study 8062489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2839025 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg Calcium and 25 micrograms cholecalciferol per day
Number of subjects: 92
Study 2839025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 31524828 — intervention group
Group type: EXPERIMENTAL
Intervention: 13‐wk exercise program (n = 39)
Number of subjects: 70
Study 31524828 — intervention group
Group type: COMPARATOR
Intervention: Usual lifestyle control group (n = 31)
Number of subjects: 70
Study 29310711 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative pharmaceutical care with medication reconciliation and review performed by a clinical pharmacist during the experimental period
Number of subjects: 630
Study 29310711 — intervention group
Group type: COMPARATOR
Intervention: Control period with no clinical pharmacist
Number of subjects: 630
Study 29310711 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative pharmaceutical care
Number of subjects: 630
Study 25586058 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon (Peg‐IFN)
Number of subjects: 791
Study 25586058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogues (NUCs)
Number of subjects: 791
Study 25586058 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anti‐HBc level
Number of subjects: 791
Study 24764070 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure and thermal dynamic sensitivity group
Number of subjects: 157
Study 24764070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pain sensitivity group
Number of subjects: 157
Study 24764070 — intervention group
Group type: EXPERIMENTAL
Intervention: High thermal static sensitivity group
Number of subjects: 157
Study 22426913 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional periodontal therapy
Number of subjects: 40
Study 22426913 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight group (control)
Number of subjects: 40
Study 22426913 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (test)
Number of subjects: 40
Study 19501976 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine supplementation
Number of subjects: 20
Study 18362869 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Number of subjects: 0
Study 16015413 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (median doses: 1.5‐2.0 mcg/kg/min)
Number of subjects: 165
Study 16015413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotherapy with Argatroban and Warfarin (median dose: 5 mg initially with 3.8 mg/day thereafter)
Number of subjects: 165
Study 16015413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotherapy with Argatroban and Warfarin
Number of subjects: 165
Study 16015413 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transitional INR data
Number of subjects: 165
Study 16015413 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 165
Study 15259476 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day primaquine regimen (15 mg/d)
Number of subjects: 273
Study 15259476 — intervention group
Group type: COMPARATOR
Intervention: No antirelapse therapy
Number of subjects: 273
Study 10997897 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg) + vaginal meteneprost (5 mg)
Number of subjects: 101
Study 10997897 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone (200 mg) + oral misoprostol (600 microg)
Number of subjects: 101
Study 8753636 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR II vaccination
Number of subjects: 580
Study 2007103 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lumbar plexus block with bupivacaine
Number of subjects: 22
Study 2007103 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine
Number of subjects: 22
Study 6762846 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg b.i.d.
Number of subjects: 20
Study 6762846 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg b.i.d.
Number of subjects: 20
Study 6762846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31309857 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (LT)
Number of subjects: 20
Study 31309857 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (EM)
Number of subjects: 20
Study 31728510 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention with anti-TNF-α treatment
Number of subjects: 360
Study 31728510 — intervention group
Group type: COMPARATOR
Intervention: Standard care (steroids and/or immunomodulators)
Number of subjects: 360
Study 29781650 — intervention group
Group type: EXPERIMENTAL
Intervention: SecondStory intervention
Number of subjects: 112
Study 29781650 — intervention group
Group type: COMPARATOR
Intervention: Expressive writing (active control)
Number of subjects: 112
Study 27509063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (EGFR inhibitor)
Number of subjects: 426
Study 27509063 — intervention group
Group type: COMPARATOR
Intervention: Nordic FLOX (5-fluorouracil and oxaliplatin)
Number of subjects: 426
Study 24439932 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fire safety DVD intervention
Number of subjects: 87
Study 22613239 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training protocol with the Biodex Balance System, 12 weeks, two sessions per week
Number of subjects: 40
Study 20858862 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg daily) concomitantly with clopidogrel
Number of subjects: 20
Study 20858862 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg daily) staggered by 8 to 12 hours with clopidogrel
Number of subjects: 20
Study 20858862 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel alone
Number of subjects: 20
Study 17600281 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 (Talpha1) as an adjunct to influenza vaccination
Number of subjects: 0
Study 17600281 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccination without thymosin alpha 1
Number of subjects: 0
Study 15167476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafil technique
Number of subjects: 60
Study 15167476 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifecta technique
Number of subjects: 60
Study 15167476 — intervention group
Group type: COMPARATOR
Intervention: Thermafil technique
Number of subjects: 60
Study 15167476 — intervention group
Group type: COMPARATOR
Intervention: Soft-Core technique
Number of subjects: 60
Study 15603047 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral antibiotics (metronidazole and cefoxitin)
Number of subjects: 72
Study 15603047 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 72
Study 9871432 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (controlled by feedback, twice daily)
Number of subjects: 0
Study 9871432 — intervention group
Group type: COMPARATOR
Intervention: Usual doses of cyclosporine and corticosteroids
Number of subjects: 0
Study 7639018 — intervention group
Group type: EXPERIMENTAL
Intervention: vaccine + low-dose DETOX (10 micrograms MPL + 100 micrograms CWS)
Number of subjects: 19
Study 7639018 — intervention group
Group type: EXPERIMENTAL
Intervention: vaccine + high-dose DETOX (20 micrograms MPL + 200 micrograms CWS)
Number of subjects: 19
Study 7639018 — intervention group
Group type: COMPARATOR
Intervention: vaccine + alum (control group)
Number of subjects: 19
Study 7639018 — intervention group
Group type: EXPERIMENTAL
Intervention: DETOX group (combined low and high dose)
Number of subjects: 19
Study 7639018 — intervention group
Group type: EXPERIMENTAL
Intervention: DETOX group
Number of subjects: 19
Study 7639018 — intervention group
Group type: COMPARATOR
Intervention: alum group (control)
Number of subjects: 19
Study 2535054 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg b.i.d.
Number of subjects: 10
Study 2535054 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg b.i.d.
Number of subjects: 10
Study 2535054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 365541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary lithium carbonate (1.80 g = 24.3 mmol)
Number of subjects: 0
Study 365541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release lithium carbonate (1.80 g = 24.3 mmol)
Number of subjects: 0
Study 365541 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (ordinary preparation)
Number of subjects: 0
Study 365541 — intervention group
Group type: COMPARATOR
Intervention: Manic subjects (sustained-release preparation)
Number of subjects: 0
Study 31171471 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial percutaneous coronary intervention (TRI)
Number of subjects: 41
Study 31405567 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl Starch
Number of subjects: 30
Study 31405567 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin
Number of subjects: 30
Study 31405567 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloids
Number of subjects: 30
Study 31405567 — intervention group
Group type: COMPARATOR
Intervention: Intem test
Number of subjects: 30
Study 29062324 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (5000 IU) and Vitamin C (2600 mg) supplementation for 1 month
Number of subjects: 90
Study 29062324 — intervention group
Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 90
Study 26121423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 506
Study 26121423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study 23083379 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (5000 IU · day(‐1) for 8 weeks)
Number of subjects: 91
Study 23083379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 21628364 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly vitamin D supplements (35 µg/week) for six months
Number of subjects: 2079
Study 21628364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2079
Study 19352187 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine infiltration after induction of general anaesthesia (Group A)
Number of subjects: 96
Study 19352187 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine infiltration before the end of surgery (Group B)
Number of subjects: 96
Study 19352187 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 96
Study 16966109 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (clindamycin-gentamycin)
Number of subjects: 84
Study 16966109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 15580197 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid advancement to higher achieved formula concentration (2-day transition)
Number of subjects: 0
Study 15580197 — intervention group
Group type: COMPARATOR
Intervention: Usual care (5-day transition, lower concentration target)
Number of subjects: 0
Study 11423708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate withdrawal (40 mg isosorbide dinitrate twice daily)
Number of subjects: 29
Study 11423708 — intervention group
Group type: COMPARATOR
Intervention: Placebo withdrawal
Number of subjects: 29
Study 11423708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate withdrawal
Number of subjects: 29
Study 9290604 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 3.2% ALA (LA/ALA ratio, 4.8)
Number of subjects: 0
Study 9290604 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 0.4% ALA (LA/ALA ratio, 44)
Number of subjects: 0
Study 9290604 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 0
Study 8451922 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% Sodium Lauryl Sulfate (SLS) dentifrice
Number of subjects: 10
Study 8451922 — intervention group
Group type: COMPARATOR
Intervention: 0.0% Sodium Lauryl Sulfate (SLS) dentifrice (control)
Number of subjects: 10
Study 3780125 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ 28,668 (doses ranging from 25 to 1200 mg)
Number of subjects: 56
Study 3780125 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ 28,668
Number of subjects: 56
Study 3780125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 30969342 — intervention group
Group type: EXPERIMENTAL
Intervention: D-CPT
Number of subjects: 88
Study 30969342 — intervention group
Group type: COMPARATOR
Intervention: WL/TA
Number of subjects: 88
Study 30266412 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric everolimus‐eluting BVS (Absorb)
Number of subjects: 2604
Study 30266412 — intervention group
Group type: COMPARATOR
Intervention: Cobalt‐chromium everolimus‐eluting stents (EES)
Number of subjects: 2604
Study 27959712 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral internal-thoracic-artery grafting
Number of subjects: 3102
Study 27959712 — intervention group
Group type: COMPARATOR
Intervention: Single internal-thoracic-artery grafting
Number of subjects: 3102
Study 24296867 — intervention group
Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (MK-7, vitamin K2) supplementation
Number of subjects: 110
Study 22425129 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity extracorporeal shock wave therapy
Number of subjects: 67
Study 22425129 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 67
Study 20110563 — intervention group
Group type: EXPERIMENTAL
Intervention: Single retinyl palmitate dose of 200,000 IU (S1)
Number of subjects: 199
Study 20110563 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of retinyl palmitate 200,000 IU 24 hours apart (S2)
Number of subjects: 199
Study 20110563 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (C)
Number of subjects: 199
Study 18695150 — intervention group
Group type: EXPERIMENTAL
Intervention: atrasentan
Number of subjects: 72
Study 18695150 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study 16248251 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangwei Granule (KWG)
Number of subjects: 68
Study 16248251 — intervention group
Group type: COMPARATOR
Intervention: Weifuchun (Control)
Number of subjects: 68
Study 12810415 — intervention group
Group type: COMPARATOR
Intervention: Grilled spinach alone (100g)
Number of subjects: 10
Study 12810415 — intervention group
Group type: EXPERIMENTAL
Intervention: Grilled spinach with sour cream
Number of subjects: 10
Study 12810415 — intervention group
Group type: EXPERIMENTAL
Intervention: Grilled spinach with Calci-Trim milk
Number of subjects: 10
Study 12810415 — intervention group
Group type: EXPERIMENTAL
Intervention: Grilled spinach with cottage cheese
Number of subjects: 10
Study 12810415 — intervention group
Group type: EXPERIMENTAL
Intervention: Grilled spinach with olive oil
Number of subjects: 10
Study 10678259 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 60 mg
Number of subjects: 0
Study 10678259 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg
Number of subjects: 0
Study 10678259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10678259 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (both dosages)
Number of subjects: 0
Study 9222277 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 10(7) irradiated 14932/IL‐2 melanoma cells
Number of subjects: 12
Study 9222277 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 x 10(7) irradiated 14932/IL‐2 melanoma cells
Number of subjects: 12
Study 9222277 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 10(7) cells of the second line (1B6/IL‐2)
Number of subjects: 12
Study 9222277 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 12
Study 8350584 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic vancomycin (10 mg/kg/day in two doses)
Number of subjects: 76
Study 8350584 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vancomycin)
Number of subjects: 76
Study 8350584 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin plus oral cefixime for patients with positive cultures for gram-negative organisms
Number of subjects: 76
Study 8350584 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cefixime)
Number of subjects: 76
Study 3001520 — intervention group
Group type: EXPERIMENTAL
Intervention: vidarabine (15 mg/kg/day for 10 days)
Number of subjects: 208
Study 3001520 — intervention group
Group type: COMPARATOR
Intervention: acyclovir (30 mg/kg/day for 10 days)
Number of subjects: 208
Study 3001520 — intervention group
Group type: EXPERIMENTAL
Intervention: vidarabine
Number of subjects: 208
Study 3001520 — intervention group
Group type: COMPARATOR
Intervention: acyclovir
Number of subjects: 208
Study 29622512 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin coated grafts
Number of subjects: 431
Study 29622512 — intervention group
Group type: COMPARATOR
Intervention: Standard polytetrafluoroethylene grafts
Number of subjects: 431
Study 27234670 — intervention group
Group type: COMPARATOR
Intervention: Single-task balance training
Number of subjects: 42
Study 27234670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task balance training
Number of subjects: 42
Study 24832424 — intervention group
Group type: COMPARATOR
Intervention: Standard SURI program (S)
Number of subjects: 230
Study 24832424 — intervention group
Group type: EXPERIMENTAL
Intervention: SURI plus Internet behavioral program (SI)
Number of subjects: 230
Study 24832424 — intervention group
Group type: EXPERIMENTAL
Intervention: SI plus optional group sessions (SIG)
Number of subjects: 230
Study 23724618 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 75
Study 23724618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 21095446 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 337
Study 21095446 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 337
Study 18769484 — intervention group
Group type: EXPERIMENTAL
Intervention: One SMBG per week (low frequency)
Number of subjects: 202
Study 18769484 — intervention group
Group type: COMPARATOR
Intervention: Four SMBG per week (high frequency)
Number of subjects: 202
Study 18769484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (low and high frequency)
Number of subjects: 202
Study 16614863 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Ceramic Crowns (PCC) (Vita MarkII/Cerec III)
Number of subjects: 29
Study 16614863 — intervention group
Group type: COMPARATOR
Intervention: Cast Gold Partial Crowns (CGPC) (Degulor C)
Number of subjects: 29
Study 12639494 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of inactivated poliovirus vaccine (IPV) at 6, 10, and 14 weeks together with oral poliovirus vaccine (OPV)
Number of subjects: 1429
Study 12639494 — intervention group
Group type: EXPERIMENTAL
Intervention: One additional dose of IPV at 14 weeks together with the last dose of OPV
Number of subjects: 1429
Study 12639494 — intervention group
Group type: COMPARATOR
Intervention: EPI schedule (OPV at birth and at 6, 10, and 14 weeks)
Number of subjects: 1429
Study 11203035 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression Education Program (DEP)
Number of subjects: 150
Study 8773088 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg daily for 2 weeks and then tapered off)
Number of subjects: 46
Study 8773088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 28972265 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (WBI) - Partners Connect; Duration: four sessions
Number of subjects: 312
Study 28972265 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 312
Study 26740276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifenthrin (acaricide)
Number of subjects: 2727
Study 26740276 — intervention group
Group type: COMPARATOR
Intervention: Water (placebo control)
Number of subjects: 2727
Study 23995520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen milk formulation
Number of subjects: 40
Study 23995520 — intervention group
Group type: COMPARATOR
Intervention: Sunscreen gel formulation
Number of subjects: 40
Study 22859796 — intervention group
Group type: EXPERIMENTAL
Intervention: REG1 with 25% anivamersen reversal
Number of subjects: 640
Study 22859796 — intervention group
Group type: EXPERIMENTAL
Intervention: REG1 with 50% anivamersen reversal
Number of subjects: 640
Study 22859796 — intervention group
Group type: EXPERIMENTAL
Intervention: REG1 with 75% anivamersen reversal
Number of subjects: 640
Study 22859796 — intervention group
Group type: EXPERIMENTAL
Intervention: REG1 with 100% anivamersen reversal
Number of subjects: 640
Study 22859796 — intervention group
Group type: COMPARATOR
Intervention: Heparin (control)
Number of subjects: 640
Study 22859796 — intervention group
Group type: EXPERIMENTAL
Intervention: REG1 (combined)
Number of subjects: 640
Study 20954636 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 75
Study 20954636 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 75
Study 20954636 — intervention group
Group type: COMPARATOR
Intervention: Image-free navigation system
Number of subjects: 75
Study 18625073 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination botanical product (CBP) 2 tablets three times a day
Number of subjects: 20
Study 18625073 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once a day
Number of subjects: 20
Study 18625073 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination botanical product (CBP)
Number of subjects: 20
Study 18625073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18625073 — intervention group
Group type: EXPERIMENTAL
Intervention: None of the treatments
Number of subjects: 20
Study 15911464 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir for 365 days
Number of subjects: 703